Stock Analysis

Insider Confidence In Top Growth Companies For November 2024

Published

As global markets experience a broad-based rally, with U.S. indexes nearing record highs and smaller-cap stocks outperforming their larger counterparts, investor sentiment is buoyed by strong labor market data and positive housing reports. Amidst this backdrop of economic optimism, growth companies with high insider ownership can be particularly appealing as they often signal management's confidence in the company's potential to navigate current uncertainties and capitalize on opportunities for expansion.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
People & Technology (KOSDAQ:A137400)16.4%37.3%
Seojin SystemLtd (KOSDAQ:A178320)31.1%43.2%
Archean Chemical Industries (NSEI:ACI)22.9%41.3%
SKS Technologies Group (ASX:SKS)32.4%24.8%
Medley (TSE:4480)34%31.7%
Findi (ASX:FND)34.8%71.5%
Plenti Group (ASX:PLT)12.8%120.1%
Fulin Precision (SZSE:300432)13.6%66.7%
Brightstar Resources (ASX:BTR)16.2%84.6%
Global Tax Free (KOSDAQ:A204620)19.9%67.5%

Click here to see the full list of 1515 stocks from our Fast Growing Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Pharmanutra (BIT:PHN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pharmanutra S.p.A. is a pharmaceutical and nutraceutical company that focuses on researching, designing, developing, and marketing nutritional supplements and medical devices across Italy, Europe, the Middle East, South America, the Far East, and internationally with a market cap of €532.28 million.

Operations: The company's revenue segments are comprised of €5.49 million from Akern, €68.35 million from Italy, and €38.40 million from international markets outside Italy.

Insider Ownership: 10.7%

Earnings Growth Forecast: 18.5% p.a.

Pharmanutra's recent earnings report shows strong growth, with sales reaching €83.47 million for the first nine months of 2024, up from €71.43 million a year ago. The company's revenue and net income have also increased significantly, reflecting robust financial health. Although insider trading data over the past three months is unavailable, analysts agree on a potential stock price rise of 52.2%. Pharmanutra's earnings are forecast to grow at 18.5% annually, outpacing the Italian market average of 7.3%.

BIT:PHN Ownership Breakdown as at Nov 2024

Geo Energy Resources (SGX:RE4)

Simply Wall St Growth Rating: ★★★★★★

Overview: Geo Energy Resources Limited is an investment holding company involved in the mining, production, and trading of coal with a market cap of SGD378.49 million.

Operations: Geo Energy Resources Limited generates revenue through its operations in coal mining, production, and trading.

Insider Ownership: 33.5%

Earnings Growth Forecast: 72% p.a.

Geo Energy Resources' strong insider ownership aligns with its growth trajectory, as insiders have substantially increased their holdings recently. The company is expected to see significant earnings growth of 72% annually, outpacing the Singapore market. Despite trading well below estimated fair value and facing challenges with dividend coverage from free cash flows, Geo Energy's strategic infrastructure developments in Indonesia aim to enhance logistical efficiency and diversify revenue streams, supporting its billion-dollar energy group vision.

SGX:RE4 Earnings and Revenue Growth as at Nov 2024

Hangzhou Juheshun New MaterialLTD (SHSE:605166)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Hangzhou Juheshun New Material Co., LTD, along with its subsidiaries, focuses on the research, development, manufacture, and sale of polyamide-6 chips across China and various international markets including Europe and South America; it has a market cap of approximately CN¥3.60 billion.

Operations: The company's revenue primarily comes from the production and sale of nylon chips, amounting to CN¥6.97 billion.

Insider Ownership: 24.5%

Earnings Growth Forecast: 26.2% p.a.

Hangzhou Juheshun New Material Co., LTD demonstrates strong growth potential with earnings forecasted to rise 26.2% annually, surpassing the Chinese market average. The company reported a notable increase in net income to CNY 233.63 million for the nine months ending September 2024, reflecting a significant year-over-year improvement. Trading at a substantial discount to its estimated fair value and with no recent insider selling, it offers attractive relative value compared to peers and industry standards.

SHSE:605166 Ownership Breakdown as at Nov 2024

Summing It All Up

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're here to simplify it.

Discover if Hangzhou Juheshun New MaterialLTD might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com